Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer
- Trial ID:
- IRB-19-7391
- Munveer S Bhangoo, MD
Inclusion Criteria
Patients must:
- Be 18 years of age or older
Have a confirmed diagnosis of Muscle invasive Bladder Cancer (MIBC), Clinical Stage T2-T4aN0M0
Be eligible to receive cisplatin chemotherapy.
Be eligible for surgical treatment and agree to planned surgical treatment
Exclusion Criteria
Patients must not:
- Have received any prior systemic anti-cancer treatment for MIBC
Be pregnant or breastfeeding or expecting to conceive or father children within the defined study duration
Have a known history of HIV, Hepatitis B, or active Hepatitis C
Additional Info
All patients will receive chemotherapy (cisplatin + gemcitabine) and surgery, and will be randomly selectedto receive either pembrolizumab or placebo.
All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines. Study
treatment will occur for approximately 1 year and patients will be followed for up to 5 years after treatment has ended.
For more information, search for NCT03924856 at www.clinicaltrials.gov
Contact Info:
- Clinical Research Services
- CRSLeadership@scrippshealth.org
Why isn't this trial accepting new patients?
The trial may have a limited enrollment number, reached its maximum, or come to the end of its enrollment period. View trials that are recruiting
How else can Scripps help me?
We have a broad range of physician expertise and specialized medical services available. You can find a doctor online, call 1-800-SCRIPPS (1-800-727-4777) for personal help, or see related Scripps services.
How can I find trials that are accepting new participants?
For more information, see a list of trials that are recruiting, or call the clinical research office at 858-648-6402 for help.